Table 1.
Characteristics of the 133 patients with colorectal liver oligometastasis.
| Parameters | Total Patients (n = 133, %) |
|---|---|
| Patient characteristics | |
| Median age (years) | 57.8 (25–78) |
| Age, year | |
| ≤60 | 82 (61.7) |
| >60 | 51 (38.3) |
| Sex | |
| Male | 80 (60.2) |
| Female | 53 (39.8) |
| Hepatitis B virus infection | |
| Negative | 114 (85.7) |
| Positive | 19 (14.3) |
| Primary tumour location | |
| Right-side colon | 34 (25.6) |
| Left-side colon | 50 (37.6) |
| Rectum | 49 (36.8) |
| Primary tumour differentiation | |
| Well to moderate | 98 (73.7) |
| Poor | 35 (26.3) |
| T stage a | |
| 1–3 | 82 (61.7) |
| 4 | 51 (38.3) |
| N stage a | |
| 0 | 44 (33.1) |
| 1–2 | 89 (66.9) |
| Timing of metastasis | |
| Synchronous | 86 (64.7) |
| Metachronous | 47 (35.3) |
| Metastasis diameter (cm) | |
| Median (range) | 2.5 (0.3–12) |
| ≤3 | 93 (69.9) |
| >3 | 40 (31.1) |
| Median liver resection margin (cm) | 1.0 (0–3.5) |
| MSKCC-CRS | |
| 0 | 10 (7.5) |
| 1 | 49 (36.8) |
| 2 | 66 (49.6) |
| 3 | 7 (5.3) |
| 4 | 1 (0.8) |
| Adjuvant chemotherapy | |
| Oxaliplatin-based regimen | 72 (54.1) |
| Irinotecan-based regimen | 14 (10.5) |
| 5-Fu alone | 5 (3.8) |
| No | 42 (31.6) |
a Disease stage was classified according to the 2010 American Joint Committee on Cancer/International Union Against Cancer (AJCC/UICC) staging system. Abbreviations: MSKCC-CRS, Memorial Sloan–Kettering Cancer Center clinical risk score.